Cwm, LLC Viking Therapeutics, Inc. Transaction History

Cwm, LLC

$28.4 Billion
Q2 2025

A detailed history of Cwm, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cwm, LLC holds 6,355 shares of VKTX stock, worth $210,986. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,355

Previous 3,542 79.42%

Holding current value

$210,986

Previous $86,000 95.35%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 25, 2025	BUY	$19.98 - $29.49 $56,203 - $82,955	2,813 Added 79.42%	6,355 $168,000
Q1 2025 May 01, 2025	BUY	$24.15 - $42.89 $22,676 - $40,273	939 Added 36.07%	3,542 $86,000
Q4 2024 Feb 04, 2025	BUY	$38.28 - $78.03 $21,704 - $44,243	567 Added 27.85%	2,603 $105,000
Q3 2024 Oct 08, 2024	BUY	$49.84 - $70.47 $25,817 - $36,503	518 Added 34.12%	2,036 $129,000
Q2 2024 Jul 09, 2024	BUY	$47.39 - $80.2 $29,760 - $50,365	628 Added 70.56%	1,518 $80,000
Q1 2024 Apr 05, 2024	SELL	$17.4 - $94.5 $63,475 - $344,736	-3,648 Reduced 80.39%	890 $73,000
Q4 2023 Feb 01, 2024	BUY	$9.24 - $19.64 $138 - $294	15 Added 0.33%	4,538 $84,000
Q2 2023 Aug 03, 2023	SELL	$14.84 - $24.79 $1,394 - $2,330	-94 Reduced 2.04%	4,523 $73,000
Q1 2023 Apr 28, 2023	BUY	$8.08 - $17.33 $3,159 - $6,776	391 Added 9.25%	4,617 $77,000
Q4 2022 Feb 01, 2023	SELL	$2.72 - $9.4 $157 - $545	-58 Reduced 1.35%	4,226 $40,000
Q3 2022 Oct 27, 2022	SELL	$2.55 - $3.89 $1,088 - $1,661	-427 Reduced 9.06%	4,284 $12,000
Q2 2022 Jul 28, 2022	SELL	$2.11 - $3.15 $2,738 - $4,088	-1,298 Reduced 21.6%	4,711 $14,000
Q1 2022 Apr 21, 2022	BUY	$3.0 - $4.88 $5,820 - $9,467	1,940 Added 47.68%	6,009 $18,000
Q4 2021 Jan 31, 2022	BUY	$4.6 - $6.72 $317 - $463	69 Added 1.73%	4,069 $19,000
Q4 2020 Sep 15, 2021	SELL	$5.3 - $6.71 $18,841 - $23,854	-3,555 Reduced 47.05%	4,000 $24,000
Q4 2020 Jan 27, 2021	BUY	$5.3 - $6.71 $18,841 - $23,854	3,555 Added 88.88%	7,555 $43,000
Q3 2020 Sep 15, 2021	SELL	$5.73 - $8.11 $20,370 - $28,831	-3,555 Reduced 47.05%	4,000 $24,000
Q3 2020 Oct 19, 2020	BUY	$5.73 - $8.11 $20,370 - $28,831	3,555 Added 88.88%	7,555 $44,000
Q2 2020 Sep 15, 2021	SELL	$4.35 - $8.08 $14,594 - $27,108	-3,355 Reduced 45.62%	4,000 $24,000
Q2 2020 Jul 22, 2020	BUY	$4.35 - $8.08 $14,594 - $27,108	3,355 Added 83.88%	7,355 $53,000
Q1 2020 Sep 15, 2021	BUY	$3.45 - $7.95 $13,800 - $31,800	4,000 New	4,000 $24,000
Q1 2020 Apr 28, 2020	SELL	$3.45 - $7.95 $13,800 - $31,800	-4,000 Closed	0 $0
Q4 2019 Sep 14, 2021	BUY	$6.38 - $8.73 $25,520 - $34,920	4,000 New	4,000 $24,000
Q4 2019 Jan 27, 2020	SELL	$6.38 - $8.73 $25,520 - $34,920	-4,000 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$6.55 - $8.6 $26,200 - $34,400	4,000 New	4,000 $24,000
Q3 2019 Oct 22, 2019	SELL	$6.55 - $8.6 $26,200 - $34,400	-4,000 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$7.67 - $10.63 $30,680 - $42,520	4,000 New	4,000 $24,000
Q2 2019 Jul 31, 2019	SELL	$7.67 - $10.63 $30,680 - $42,520	-4,000 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$7.58 - $9.94 $30,191 - $39,591	3,983 Added 23429.41%	4,000 $0
Q1 2019 Apr 22, 2019	BUY	$7.58 - $9.94 $128 - $168	17 New	17 $0

Others Institutions Holding VKTX

# of Institutions

446

Shares Held

65.5M

Call Options Held

8.28M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.55B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account